Bamco Inc. NY Sells 39,378 Shares of Illumina, Inc. $ILMN

Bamco Inc. NY reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 208,094 shares of the life sciences company’s stock after selling 39,378 shares during the period. Bamco Inc. NY owned 0.14% of Illumina worth $19,763,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ILMN. Assetmark Inc. boosted its position in shares of Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares in the last quarter. Versant Capital Management Inc increased its holdings in Illumina by 8.9% in the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after purchasing an additional 111 shares in the last quarter. Archer Investment Corp lifted its stake in Illumina by 12.9% in the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after buying an additional 123 shares during the period. Callan Family Office LLC boosted its holdings in shares of Illumina by 4.4% during the 3rd quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after buying an additional 124 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Illumina by 4.7% during the 3rd quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock worth $269,000 after buying an additional 128 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.17% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $118.94 on Monday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a fifty day simple moving average of $133.15 and a two-hundred day simple moving average of $120.10. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The firm has a market capitalization of $18.19 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 2.28 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the subject of several research analyst reports. Canaccord Genuity Group lifted their price objective on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Evercore set a $150.00 target price on shares of Illumina in a research note on Friday, February 6th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Barclays lifted their price target on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Finally, TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.